Prescription medicine
Droxidopa Brand names: Northera
Droxidopa (Northera) is a prescription medicine with an FDA approval on record since 2014. FDA's NDC Directory lists it from 14 generic labelers, and pharmacies paid $0.472 per droxidopa 100 mg capsule in the October 7, 2026 NADAC survey.
- Generic listed
- Boxed warning
Check it at the source: the droxidopa FDA label on DailyMed (effective July 1, 2019, Lundbeck Pharmaceuticals LLC); the NDA 203202 record on Drugs@FDA; every droxidopa label on DailyMed.
Highlights of the record
FDA label of July 1, 2019; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
SUPINE HYPERTENSION.
Monitor supine blood pressure prior to and during treatment and more frequently when increasing doses. Elevating the head of the bed lessens the risk of supine hypertension, and blood pressure should be measured in this position. If supine hypertension cannot be managed by elevation of the head of the bed, reduce or discontinue NORTHERA [see Warnings and Precautions ( 5.1 )]. WARNING: SUPINE HYPERTENSION See full prescribing information for complete boxed warning. Monitor supine blood pressure prior to and during treatment and more frequently when increasing doses. Elevating the head of the bed lessens the risk of supine hypertension, and blood pressure should be measured in this position. If supine hypertension cannot be managed by elevation of the head of the bed, reduce or discontinue NORTHERA [see Warnings and Precautions ( 5.1 )].
Used for
From the label: indications and usageNORTHERA is indicated for the treatment of orthostatic dizziness, lightheadedness, or the “feeling that you are about to black out” in adult patients with symptomatic neurogenic orthostatic hypotension (nOH) caused by primary autonomic failure (Parkinson's disease [PD], multiple system atrophy, and pure autonomic failure), dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy.
Forms and strengths
- 100 mg
- 200 mg
- 300 mg
Capsule.
On the market
- Earliest approval on file
- February 18, 2014 Northera, Lundbeck Na Ltd; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- 16 first February 18, 2021; 11 with a marketed status in Drugs@FDA
- Labelers listed (NDC)
- 15 of which 14 under generic applications, 1 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- $0.472 per capsule Droxidopa 100 mg capsule
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 21,452 through July 30, 2026
What is droxidopa used for?
From the label: indications and usageNORTHERA is indicated for the treatment of orthostatic dizziness, lightheadedness, or the “feeling that you are about to black out” in adult patients with symptomatic neurogenic orthostatic hypotension (nOH) caused by primary autonomic failure (Parkinson's disease [PD], multiple system atrophy, and pure autonomic failure), dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy. Effectiveness beyond 2 weeks of treatment has not been established. The continued effectiveness of NORTHERA should be assessed periodically. […]
Source: FDA drug label (Northera), Lundbeck Pharmaceuticals LLC, effective July 1, 2019 (SPL set 2179f02c-48d7-48eb-8007-5ae43d8d16bc), via openFDA; the full label on DailyMed
Is there a generic for droxidopa (Northera)?
The FDA approved the first generic droxidopa on February 18, 2021. 16 generic applications are approved; 11 of them carry a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale.
FDA's NDC Directory lists droxidopa from 14 labelers under a generic (ANDA) application and from 1 brand labeler. A listing means the company has registered the product for sale; it does not show that every pharmacy stocks it.
- 2014 earliest approval on file
- 2021 first generic approved
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for droxidopa (Northera)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $0.472 per Droxidopa 100 mg capsule, down 49% from $0.925 on October 8, 2025. The survey records the price, not the reason for a change; large moves often follow a new generic or a list-price change. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Droxidopa 100 mg capsule (generic)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Droxidopa 100 mg capsule | Generic | $0.472 per capsule | $14.17 | -49% |
| Droxidopa 200 mg capsule | Generic | $0.901 per capsule | $27.02 | -43% |
| Droxidopa 300 mg capsule | Generic | $1.84 per capsule | $55.33 | -16% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
What does the droxidopa label say about other medicines?
The droxidopa label names 7 other medicines in its interaction, contraindication or warning sections. The labels of 1 other medicine name droxidopa. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Aspirin | warnings and precautions | Although the overall incidence of FD&C Yellow No. 5 (tartrazine) sensitivity in the general population is low, it is frequently seen in patients who also have aspirin hypersensitivity [see Contraindications ( 4 )]. |
| Ephedrine | drug interactions | Drugs that Increase Blood Pressure Administering NORTHERA in combination with other agents that increase blood pressure (e.g., norepinephrine, ephedrine, midodrine, and triptans) would be expected to increase the risk for supine hypertension. |
| Levodopa | warnings and precautions | Observe patients carefully when the dosage of NORTHERA is changed or when concomitant levodopa is reduced abruptly or discontinued, especially if the patient is receiving neuroleptics. |
| Linezolid | drug interactions | However, based on mechanism of action, the use of non-selective MAO inhibitors and linezolid should be avoided as there is a potential for increased blood pressure when taken with NORTHERA. |
| Midodrine | drug interactions | Drugs that Increase Blood Pressure Administering NORTHERA in combination with other agents that increase blood pressure (e.g., norepinephrine, ephedrine, midodrine, and triptans) would be expected to increase the risk for supine hypertension. |
| Rasagiline | drug interactions | The concomitant use of selective MAO-B inhibitors, such as rasagiline or selegiline, was permitted in the NORTHERA clinical trials. |
| Selegiline | drug interactions | The concomitant use of selective MAO-B inhibitors, such as rasagiline or selegiline, was permitted in the NORTHERA clinical trials. |
Source: FDA drug label (Northera), Lundbeck Pharmaceuticals LLC, effective July 1, 2019 (SPL set 2179f02c-48d7-48eb-8007-5ae43d8d16bc), via openFDA; the full label on DailyMed
What do FAERS reports show for droxidopa?
The FDA Adverse Event Reporting System holds 21,452 reports that list droxidopa among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 2,822 are coded as a death and 3,381 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What next?
- Droxidopa side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other